Abstract
PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors – sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®) - are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio®) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena®), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experimental and clinical data concerning their effects on different tissues, organs and systems is systematically reviewed and their possible beneficial action in numerous disorders is presented.
Keywords: PDE5 inhibitors, sildenafil, vardenafil, tadafil
Current Pharmaceutical Design
Title: PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Volume: 15 Issue: 30
Author(s): D. Kouvelas, A. Goulas, G. Papazisis, C. Sardeli and C. Pourzitaki
Affiliation:
Keywords: PDE5 inhibitors, sildenafil, vardenafil, tadafil
Abstract: PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors – sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®) - are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio®) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena®), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experimental and clinical data concerning their effects on different tissues, organs and systems is systematically reviewed and their possible beneficial action in numerous disorders is presented.
Export Options
About this article
Cite this article as:
Kouvelas D., Goulas A., Papazisis G., Sardeli C. and Pourzitaki C., PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile, Current Pharmaceutical Design 2009; 15 (30) . https://dx.doi.org/10.2174/138161209789206971
DOI https://dx.doi.org/10.2174/138161209789206971 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Lysophospholipid Receptors as Potential Drug Targets in Tissue Transplantation and Autoimmune Diseases
Current Pharmaceutical Design Pulmonary Hypertension in COPD: Pathophysiology and Therapeutic Targets
Current Drug Targets Bothrops pauloensis Snake Venom Toxins: The Search for New Therapeutic Models
Current Topics in Medicinal Chemistry Steroids and Vasopressor-Resistant Hypotension in Preterm Infants
Current Pediatric Reviews <i>Ferulago angulata</i> as a Good Radioprotector Against Genotoxicity
Current Radiopharmaceuticals Clinical Significance of the Blood Pressure Changes from Day to Night
Current Hypertension Reviews Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Anorexia Nervosa and the Use of Total Parenteral Nutrition Refeeding
Current Nutrition & Food Science Statins and Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis
Current Pharmaceutical Design High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice
Current Cardiology Reviews Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Preface: Additional Potential Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Antagonists
Current Pharmaceutical Design Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney
Current Medicinal Chemistry Endothelin-1 Actions on Vascular Smooth Muscle Cell Functions As a Target for the Prevention of Atherosclerosis
Current Vascular Pharmacology Renal Sympathetic Denervation and Renal Physiology
Current Clinical Pharmacology Sedation in PACU: The Role of Propofol
Current Drug Targets Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease
Current Vascular Pharmacology